# Revtorpyk Phase III Data: 9.3-Month Median PFS vs 2.0 Months on Comparator

> clinical trial · REPORTED · 2026-07-14

Supporting the July 14 approval, pivotal CELCI-338 trial data showed Revtorpyk-treated patients remained progression-free a median of 9.3 months versus 2.0 months for patients on fulvestrant alone, underpinning the first-in-class PAM inhibitor's regulatory clearance.

About Celcuity: Celcuity is a Minneapolis-based biotech that develops targeted oncology therapies focused on the PI3K/AKT/mTOR pathway, primarily for hormone receptor-positive breast cancer and other solid tumors.

- Company: Celcuity
- Sector: oncology
- Primary source: https://medcitynews.com/2026/07/celcuity-fda-approved-breast-cancer-revtorpyk-gedatolisib-pik3ca-pam-celc/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.